Vertex Pharmaceuticals (WBO:VRTX) LT-Debt-to-Total-Asset: 0.08 (As of Mar. 2026)

What is Vertex Pharmaceuticals LT-Debt-to-Total-Asset?

Vertex Pharmaceuticals WBO:VRTX +0.67% 86 LT-Debt-to-Total-Asset is 0.08 as of Mar. 2026. GuruFocus rates WBO:VRTX with a GF Score™ of 86/100 and a GF Value™ of €443.21 (Fairly Valued). The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Vertex Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.08.

Vertex Pharmaceuticals's long-term debt to total assets ratio increased from Mar. 2025 (0.07) to Mar. 2026 (0.08). It may suggest that Vertex Pharmaceuticals is progressively becoming more dependent on debt to grow their business.

Vertex Pharmaceuticals (WBO:VRTX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Vertex Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Vertex Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Vertex Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vertex Pharmaceuticals LT-Debt-to-Total-Asset Chart

Vertex Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.07

0.05

0.03

0.07

0.08

Vertex Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.07	0.06	0.07	0.08	0.08

86GF Score

Vertex Pharmaceuticals Inc WBO:VRTX

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Vertex Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Vertex Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	1668.033	/	21899.122
	=	0.08

Vertex Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	1718.322	/	22909.006
	=	0.08

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.08 mean?

Vertex Pharmaceuticals (WBO:VRTX) has a LT-Debt-to-Total-Asset of 0.08 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Vertex Pharmaceuticals and its competitors.

Is Vertex Pharmaceuticals' LT-Debt-to-Total-Asset too high?

Vertex Pharmaceuticals' current LT-Debt-to-Total-Asset is 0.08. Overall, Vertex Pharmaceuticals has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does Vertex Pharmaceuticals' LT-Debt-to-Total-Asset compare to REGN and ALNY?

Vertex Pharmaceuticals' LT-Debt-to-Total-Asset of 0.08 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Vertex Pharmaceuticals and its competitors. Vertex Pharmaceuticals's current LT-Debt-to-Total-Asset is 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Vertex Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, Vertex Pharmaceuticals (WBO:VRTX) is currently considered Fairly Valued. The stock's GF Value™ is €443.21, compared to a current price of €438.30 — trading 1.1% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.08. Vertex Pharmaceuticals' overall GF Score™ is 86/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Vertex Pharmaceuticals (WBO:VRTX), the current LT-Debt-to-Total-Asset is 0.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vertex Pharmaceuticals (WBO:VRTX) Overvalued in 2026?

Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued. The current stock price of €438.30 is trading 1.1% below its estimated GF Value™ of €443.21. GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.

Key valuation signals for WBO:VRTX:

LT-Debt-to-Total-Asset: 0.08
GF Value™: €443.21 vs. price of €438.30 (1.1% below fair value)
GF Score™: 86/100 with 4 warning signs

No single metric tells the full story. See the WBO:VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vertex Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies REGN ALNY RVMD ONC MRNA RPRX ROIV BNTX INCY INSM XBRU:UCB XBRU:ARGX XKRX:207940 ASX:CSL XKRX:068270 HKSE:02269 ASND HKSE:01801 OCSE:GMAB JAZZ

Other Exchanges VRTX:USA VRTX:Mexico 1VRTX:Italy 0QZU:UK VX1:Germany VRTX34:Brazil

Address 50 Northern Avenue, Boston, MA, USA, 02210

Website https://www.vrtx.com

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

86GF Score

Get the complete analysis for WBO:VRTX

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€438.30

Price

€443.21

GF Value

View WBO:VRTX Analysis

See LT-Debt-to-Total-Asset data for all stocks →